Dataset Information

Alzheimer's biomarkers in daily practice (ABIDE) project: Rationale and design.

ABSTRACT:

Introduction

The Alzheimer's biomarkers in daily practice (ABIDE) project is designed to translate knowledge on diagnostic tests (magnetic resonance imaging [MRI], cerebrospinal fluid [CSF], and amyloid positron emission tomography [PET]) to daily clinical practice with a focus on mild cognitive impairment (MCI).

Methods

ABIDE is a 3-year project with a multifaceted design and is structured into interconnected substudies using both quantitative and qualitative research methods.

Results

Based on retrospective data, we develop personalized risk estimates for MCI patients. Prospectively, we collect MRI and CSF data from 200 patients from local memory clinics and amyloid PET from 500 patients in a tertiary setting, to optimize application of these tests in daily practice. Furthermore, ABIDE will develop strategies for optimal patient-clinician conversations.

Discussion

Ultimately, this will result in a set of practical tools for clinicians to support the choice of diagnostic tests and facilitate the interpretation and communication of their results.

SUBMITTER: de Wilde A

PROVIDER: S-EPMC5318541 | biostudies-literature | 2017

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Alzheimer's biomarkers in daily practice (ABIDE) project: Rationale and design.

de Wilde Arno A van Maurik Ingrid S IS Kunneman Marleen M Bouwman Femke F Zwan Marissa M Willemse Eline A J EA Biessels Geert Jan GJ Minkman Mirella M Pel Ruth R Schoonenboom Niki S M NS Smets Ellen M A EM Wattjes Mike P MP Barkhof Frederik F Stephens Andrew A van Lier Erik J EJ Batrla-Utermann Richard R Scheltens Philip P Teunissen Charlotte E CE van Berckel Bart N M BN van der Flier Wiesje M WM

Alzheimer's & dementia (Amsterdam, Netherlands) 20170123

<h4>Introduction</h4>The Alzheimer's biomarkers in daily practice (ABIDE) project is designed to translate knowledge on diagnostic tests (magnetic resonance imaging [MRI], cerebrospinal fluid [CSF], and amyloid positron emission tomography [PET]) to daily clinical practice with a focus on mild cognitive impairment (MCI).<h4>Methods</h4>ABIDE is a 3-year project with a multifaceted design and is structured into interconnected substudies using both quantitative and qualitative research methods.<h4 ...[more]

PMID: 28239639

Similar Datasets

Project description:ImportanceBiomarkers do not determine conversion to Alzheimer disease (AD) perfectly, and criteria do not specify how to take patient characteristics into account. Consequently, biomarker use may be challenging for clinicians, especially in patients with mild cognitive impairment (MCI).ObjectiveTo construct biomarker-based prognostic models that enable determination of future AD dementia in patients with MCI.Design, setting, and participantsThis study is part of the Alzheimer's Biomarkers in Daily Practice (ABIDE) project. A total of 525 patients with MCI from the Amsterdam Dementia Cohort (longitudinal cohort, tertiary referral center) were studied. All patients had their baseline visit to a memory clinic from September 1, 1997, through August 31, 2014. Prognostic models were constructed by Cox proportional hazards regression with patient characteristics (age, sex, and Mini-Mental State Examination [MMSE] score), magnetic resonance imaging (MRI) biomarkers (hippocampal volume, normalized whole-brain volume), cerebrospinal fluid (CSF) biomarkers (amyloid-β1-42, tau), and combined biomarkers. Data were analyzed from November 1, 2015, to October 1, 2016.Main outcomes and measuresClinical end points were AD dementia and any type of dementia after 1 and 3 years.ResultsOf the 525 patients, 210 (40.0%) were female, and the mean (SD) age was 67.3 (8.4) years. On the basis of age, sex, and MMSE score only, the 3-year progression risk to AD dementia ranged from 26% (95% CI, 19%-34%) in younger men with MMSE scores of 29 to 76% (95% CI, 65%-84%) in older women with MMSE scores of 24 (1-year risk: 6% [95% CI, 4%-9%] to 24% [95% CI, 18%-32%]). Three- and 1-year progression risks were 86% (95% CI, 71%-95%) and 27% (95% CI, 17%-41%) when MRI results were abnormal, 82% (95% CI, 73%-89%) and 26% (95% CI, 20%-33%) when CSF test results were abnormal, and 89% (95% CI, 79%-95%) and 26% (95% CI, 18%-36%) when the results of both tests were abnormal. Conversely, 3- and 1-year progression risks were 18% (95% CI, 13%-27%) and 3% (95% CI, 2%-5%) after normal MRI results, 6% (95% CI, 3%-9%) and 1% (95% CI, 0.5%-2%) after normal CSF test results, and 4% (95% CI, 2%-7%) and 0.5% (95% CI, 0.2%-1%) after combined normal MRI and CSF test results. The prognostic value of models determining any type of dementia were in the same order of magnitude although somewhat lower. External validation in Alzheimer's Disease Neuroimaging Initiative 2 showed that our models were highly robust.Conclusions and relevanceThis study provides biomarker-based prognostic models that may help determine AD dementia and any type of dementia in patients with MCI at the individual level. This finding supports clinical decision making and application of biomarkers in daily practice.

Dataset Information

Alzheimer's biomarkers in daily practice (ABIDE) project: Rationale and design.

Introduction

Methods

Results

Discussion

Publications

Alzheimer's biomarkers in daily practice (ABIDE) project: Rationale and design.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets